Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2019

01-05-2019 | Research Article

Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood

Authors: P. H. P. Liberman, M. V. S. Goffi-Gomez, C. Schultz, P. L. Jacob, C. A. A. de Paula, E. L. Sartorato, G. T. Torrezan, E. N. Ferreira, D. M. Carraro

Published in: Clinical and Translational Oncology | Issue 5/2019

Login to get access

Abstract

Background and aim

Ototoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children. Hearing loss (HL) affecting frequencies below 4 kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4 kHz in pediatric oncology patients treated with cisplatin or carboplatin.

Materials and methods

Patients given cisplatin or carboplatin for a pediatric cancer at least 5 years prior to the start of the study were enrolled. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the GJB2 c.35delG, GSTP1 c.313A>G, and MT-RNR1 m.1555A>G polymorphisms.

Results

HL was identified in 31/61 patients (50.8%), including 28/42 treated with cisplatin (66.6%) and 3/19 treated with carboplatin (15.8%). HL was associated with higher mean doses of cisplatin (p = .002) and carboplatin (p = .010). The c.313A>G variant of GSTP1 (heterozygous or homozygous) was detected in 31/61 patients (50.8%). An association between this variant allele and HL involving frequencies ≤ 4 kHz was identified (p = .020; 10-fold vs. non-carriers). No associations with HL were observed for GJB2 or MT-RNR1 gene variants.

Conclusion

The GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy.
Literature
1.
Brock PR, Yeomans EC, Bellman SC, Pritchard J. Cisplatin therapy in infants: short and long-term morbidity. Br J Cancer Suppl. 1992;18:S36–40.PubMedPubMedCentral
2.
Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer. 2004;40:2352–4.CrossRefPubMed
3.
4.
Peters U, Preisler-Adams S, Hebeisen A, Hahn M, Seifert E, Lanvers C, Heinecke A, Horst J, Jürgens H, Lamprecht-Dinnesen A. Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000;11:639–43.CrossRefPubMed
5.
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: clinical and experimental studies. Tonoku J Exp Med. 2009;219:177–86.CrossRef
6.
7.
Hyppolito MA, Oliveira JAA. Ototoxicity, otoprotection and self defense of the coclear outer hair cells. Medicina (Ribeirão Preto). 2005;38:279–89.CrossRef
8.
9.
Knoll C, Smith RJ, Shores C, Blatt J. Hearing genes and cisplatin deafness: a pilot study. Laryngoscope. 2006;116:72–4.CrossRefPubMed
10.
Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007;226(1–2):157–67.CrossRefPubMed
11.
Sabatini LM, Mathews C, Ptak D, Doshi S, Tynan K, Hegde MR, Burke TL, Bossler AD. Genomic sequencing procedure microcosting analysis and health economic cost-impact analysis: a report of the association for molecular pathology. J Mol Diagn. 2016;18(3):319–28.CrossRefPubMed
12.
Peters U, Preisler-Adams S, Lanvers-Kaminsky C, Jürgens H, Lamprecht-Dinnesen A. Sequence variations of mitochondrial DNA and individual sensitivity to theototoxic effect of cisplatin. Anticancer Res. 2003;23:1249–55.PubMed
13.
Guan MX, Fischel-Ghodsian N, Attardi G. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet. 2000;9:1787–93.CrossRefPubMed
14.
el Barbary A, Altschuler RA, Schacht J. Gluthathione S-transferases in the organ of corti of the rat: enzymatic activity, subunit composition and immunohistochemical localization. Hear Res. 1993;71:80–90.CrossRefPubMed
15.
Hu X, Xia H, Srivastava SK, Pal A, Awasthi YC, Zimniak P, Singh SV. Catalytic efficiencies of allelic variants of human glutathione S-transferase P1-1 toward carcinogenic anti-diol epoxides of benzo[c] phenan-threne and benzo[g]chrysene. Cancer Res. 1998;58:5340–3.PubMed
16.
Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012;30(19):2408–17. https://​doi.​org/​10.​1200/​JCO.​2011.​39.​1110.CrossRefPubMedPubMedCentral
17.
Liberman PHP, Goffi-Gomez MVS, Schultz C, Lopes LF. What are the audiometric frequencies affected are the responsible for the hearing complaint in the hearing loss for ototoxicity after the oncological treatment? Arq Int Otorrinolaringol. 2012;16:26–31.
18.
19.
Friedman TB, Griffith AJ. Human nonsyndromic sensori-neural deafness. Ann Rev Genom Hum Genet. 2003;4:341–402.CrossRef
20.
Iwasaki S, Tamagawa Y, Ocho S, Hoshino T, Kitamura K. Hereditary sensorineural hearing loss of unknown cause involving mitochondrial DNA A1555 mutation. ORL J Otorhinolaryngol Relat Spec. 2000;62:100–3.CrossRefPubMed
21.
Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis (Lond). 1997;18:641–4.CrossRef
22.
Jerónimo C, Varzim G, Henrique R, Oliveira J, Bento MJ, Silva C, Lopes C, Sidransky D. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomark Prev. 2002;11(5):445–50.
23.
Jehanne M, Lumbroso-Le Rouic L, Savignoni A, Aerts I, Mercier G, Bours D, Desjardins L, Doz F. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr Blood Cancer. 2009;52(5):637–43. https://​doi.​org/​10.​1002/​pbc.​21898.CrossRefPubMed
24.
25.
26.
27.
Estivill X, Govea N, Barceló E, Badenas C, Romero E, Moral L, Scozzri R, D’Urbano L, Zeviani M, Torroni A. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet. 1998;62(1):27–35.CrossRefPubMedPubMedCentral
28.
29.
Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol. 2007;25:708–14.CrossRefPubMed
30.
Metadata
Title
Contribution of the GSTP1 c.313A>G variant to hearing loss risk in patients exposed to platin chemotherapy during childhood
Authors
P. H. P. Liberman
M. V. S. Goffi-Gomez
C. Schultz
P. L. Jacob
C. A. A. de Paula
E. L. Sartorato
G. T. Torrezan
E. N. Ferreira
D. M. Carraro
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 5/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-1964-7

Other articles of this Issue 5/2019

Clinical and Translational Oncology 5/2019 Go to the issue

Correction

Correction to: SEOM clinical guideline for treatment of kidney cancer (2017)

Research Article

Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective

Special Article

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology

Research Article

Hydrogen peroxide-induced mitophagy contributes to laryngeal cancer cells survival via the upregulation of FUNDC1

Brief Research Article

Risk of malnutrition and emotional distress as factors affecting health-related quality of life in patients with resected cancer

Research Article

Additional malignancies in patients with gastrointestinal stromal tumors (GIST): incidence, pathology and prognosis according to a time of occurrence-based classification
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits